Anticancer drugs : antimetabolite metabolism and natural anticancer agents
著者
書誌事項
Anticancer drugs : antimetabolite metabolism and natural anticancer agents
（International encyclopedia of pharmacology and therapeutics, section 140）
Pergamon Press, 1994
大学図書館所蔵 全12件
注記
Includes bibliographical references and index
内容説明・目次
内容説明
There are over 50 clinically approved anticancer drugs, as well as numerous steroidal agents, and in addition there are many new anticancer drugs in various stages of preclinical and clinical development. The anticancer drugs embody a diverse array of chemical structures. The purpose of this two volume publication is to provide a comprehensive review of the metabolism of anticancer drugs. The authors, each expert in their fields, have attempted to emphasize the relation of metabolism to the therapeutic and toxic effects of anticancer drugs, drawing whenever possible on human studies. There is a critical need for new approaches to treating cancer and it is certain that we will see an increasing number of new drugs with exotic chemical structures used for chemotherapy and perhaps chemoprevention. To understand the mechanisms of action of any drug it is important to know how the drug is transformed in the body, either into active metabolites or inactive products to be excreted. With this information the success or failure of a drug in arresting cancer cell growth can be assessed, and perhaps more effective drugs designed.
Medical science has taken the first important steps toward controlling cancer. The use and study of current chemotherapeutic drugs has taught us much about how toxic chemicals can be employed to treat human cancer; comprehending the underlying metabolism of these drugs should facilitate even better modalities of treatment for the future.
目次
- Part 1 Control of cancer by amino acid analogs, G.S. Ahluwalia et al: azaserine. Part 2 Metabolism of pyrimidine analogues and their nucleosides, G.C. Daher et al: fluoropyrimidines
- azacytidine. Part 3 Metabolism and action of purine nucleoside analogs, W. Plunkett and P.P. Saunders: tiazofurin
- neplanocin A. Part 4 The basis for antifolate cytotoxicity, selectivity and metabolic transformation - effects on utilization of endogenous and exogenous folate cofactors, L.H. Matherly et al: mammalian folylpolyglutamate synthetase. Part 5 The metabolic basis for combination chemotherapy, L.E. Damon and E.C. Cadman: synergistic modulation. Part 6 The metabolism of antihormonal anticancer agents, S.P. Robinson and V.C. Jordan: treatment strategies for hormone-dependent cancers
- antiestrogens. Part 7 Metabolism of natural and synthetic steroids used in cancer treatment, R.Y. Kirdani et al: metabolism of natural and synthetic androgens used in cancer therapy. Part 8 Metabolism of plant-derived anticancer agents, G. Cragg and M. Suffness: bruceantin
- taxol. Part 9 Metabolism of protein anticancer agents, V. Bocci: cytotoxins
- tuftsin. Part 10 Metabolism of new anticancer agents, Z.H. Siddik and R.A. Newman: caracemide
- trimelamol
- flavone acetic acid
- hycamptamine
- sulofenur. Part 11 Metabolism of cancer drugs as a basis for drug resistance, S. Kuzmich and K.D. Tew: glutathione S-transferases - structure and function
- future perspectives. (Part Contents).
「Nielsen BookData」 より